Matinas BioPharma Holdings (MTNB) EBITDA (2014 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly EBITDA of -$1.9 million for Q1 2026, up 0.51% year-over-year from -$1.9 million in Q1 2025, and down 21.0% quarter-over-quarter from -$1.6 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) EBITDA (2014 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported EBITDA for 13 consecutive years, with -$1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 0.51% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$7.0 million (up 66.32% YoY), while the FY2025 annual figure was -$7.0 million, up 71.7% from the prior year.
- EBITDA eased to -$1.9 million in Q1 2026 per MTNB's latest filing, from -$1.6 million in the prior quarter.
- Across five years, EBITDA topped out at -$1.6 million in Q3 2025 and bottomed at -$8.5 million in Q4 2024.
- Historically, EBITDA has averaged -$4.8 million across 5 years, with a median of -$5.6 million in 2023.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 43.86% — and 2025, when it jumped 81.11%.
- Matinas BioPharma Holdings' EBITDA stood at -$5.5 million in 2022, then fell by 7.43% to -$5.9 million in 2023, then sank by 43.86% to -$8.5 million in 2024, then surged by 81.11% to -$1.6 million in 2025, then fell by 21.0% to -$1.9 million in 2026.
- Business Quant data shows MTNB's EBITDA at -$1.9 million in Q1 2026, -$1.6 million in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.94 Mn |
| Dec 31, 2025 | -1.60 Mn |
| Sep 30, 2025 | -1.58 Mn |
| Jun 30, 2025 | -1.84 Mn |
| Mar 31, 2025 | -1.95 Mn |
| Dec 31, 2024 | -8.47 Mn |
| Sep 30, 2024 | -4.38 Mn |
| Jun 30, 2024 | -5.84 Mn |
| Mar 31, 2024 | -5.90 Mn |
| Dec 31, 2023 | -5.89 Mn |
| Sep 30, 2023 | -6.13 Mn |
| Jun 30, 2023 | -6.16 Mn |
| Mar 31, 2023 | -5.59 Mn |
| Dec 31, 2022 | -5.48 Mn |
| Sep 30, 2022 | -5.46 Mn |
| Jun 30, 2022 | -5.93 Mn |
| Mar 31, 2022 | -7.72 Mn |
| Dec 31, 2021 | -6.71 Mn |
| Sep 30, 2021 | -6.88 Mn |